Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer

Anti-Cancer Drugs

Volumn 14, Issue 2, 2003, Pages 111-118

  Artal Cortes, Angel ^a   Martínez Trufero, Javier ^a   Herrero, Ana ^a   Puértolas, Teresa ^a   Alonso, Vicente ^a   Corral, Mónica ^a   Ceballos, Concepción ^a   Maurel, Joan ^a   Antón, Antonio ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Cisplatin; Increasing dose gemcitabine; Metastatic non small cell lung cancer; Phase I trial

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG INFUSION; FATIGUE; FEMALE; FEVER; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERFORMANCE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THROMBOCYTOSIS; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED;

EID: 0037331281     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200302000-00004     Document Type: Article

References (28)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
2. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br J Cancer 1995; 311:899-909.
3. American Society of Clinical Oncology: Special article. Clinical practice guidelines for treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15:2996-3018.
4. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 5:1087-1100.
5. Sandler A, Ettinger DS. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. Oncologist 1999; 4:241-251.
6. Rosell R, Tonato M, Sandler A. The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer. Semin Oncol 1998; 24(4 suppl 9):27s-34s.
7. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ. 2′,2′-difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 1993; 46:762-766.
8. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine in human lung cancer cell lines. Eur J Cancer 1999; 35:796-807.
9. Abbruzzese JL, Grunewald R, Week EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9:491-498.
10. Cardenal F, Lopez-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17:12-18.
11. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
12. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15:310-316.
13. Klastersky J, Sculier JP, Ravez P, Libert P, Michel J, Vandermoten G, et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma. J Clin Oncol 1986; 4:1780-1786.
14. Cullen MH, Joshi R, Chetiyawardana AD, Woodroffe CM. Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 1988; 58:359-361.
15. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188-3194.
16. Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
17. Ebbe S, Yee T, Phalen E. 5-Fluorouracil-induced thrombocytosis in mice is independent of the spleen and can be partially reproduced by repeated doses of cytosine arabinoside. Exp Hematol 1989; 17:822-826.
18. Anton A, Diaz-Fernandez N, Gonzalez-Larriba JL, Vadell C, Masutti B, Montalar J, et al. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1998; 22:139-148.
19. Peters GJ, Bergman AM, Ruiz van Harperen VWT, Veerman G, Kuiper CM, Braakhuis BJ, et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 1995; 22(4 suppl 11):72s-79s.
20. van Moorse CJ, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE, et al. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 1999; 10:441-448.
21. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130.
22. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11:873-878.
23. Shepherd FA, Burkes R, Cormier Y, Crump M, Feld R, Strack T, et al. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer: usefulness of mathematic modelling to determine maximum-tolerable dose. J Clin Oncol 1996; 14:1656-1662.
24. Green MR, Eisenberg P, Kosty M, Stolbach L, Hainsworth J, Zacnoen S, et al. Activity and tolerability of gemcitabine plus weekly cisplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1998; 17:468 (abstr).
25. Rinaldi M, Crino L, Scagliotti GV, Mosconi AM, De Marinis F, Gridelli C, et al. A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose-levels: a phase II randomized trial. Ann Oncol 2000; 11:1295-1300.
26. Kassem B, Miketic LM, Landreneau RJ, Ferson PF, Keenan R, Youssem SA, et al. Phase I study of gemcitabine given weekly as short infusion. Proc Am Soc Clin Oncol 1995; 14:383 (abstr 1190).
27. Font A, Moyano AJ, Puerto JM, Tres A, Garcia-Giron C, Barneto I, et al. Increasing dose intensity of cisplatin-etoposide in advanced non-small cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group. Cancer 1999; 85:855-863.
28. Maurel J, Puertolas T, Martinez Trufero J, Herrero A, Zorrilla M, Alonso V, et al. Phase I trial of three-hour infusion gemcitabine in refractory, heavily pretreated advanced solid tumors. Proc Am Soc Clin Oncol 2000; 19:855 (abstr).